Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1

被引：2
|
作者：
Pijak, MR [1 ]
Gazdik, F [1 ]
Hrusovsky, S [1 ]
机构：
[1] Slovak Med Univ, Dept Clin Immunol, Bratislava, Slovakia
来源：
HEPATOLOGY | 2004年 / 40卷 / 03期
关键词：
D O I：
10.1002/hep.20397
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：760 / 761
页数：2
相关论文
共 50 条
  • [1] Peginterferon Alfa-2a (40 kd) and ribavirin for Black American patients with chronic HCV genotype 1
    Jeffers, LJ
    Cassidy, W
    Howell, CD
    Hu, S
    Reddy, KR
    HEPATOLOGY, 2004, 39 (06) : 1702 - 1708
  • [2] Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1 - Reply
    Jeffers, LJ
    Cassidy, W
    Howell, CD
    Hu, S
    Reddy, KR
    HEPATOLOGY, 2004, 40 (03) : 761 - 761
  • [3] Safety and adherence to peginterferon alfa-2a (40KD) plus ribavirin (RBV) in black Americans with chronic hepatitis C (CHC) HCV genotype 1
    Howell, CD
    Jeffers, LS
    Hu, S
    Lopez-Talavera, JC
    GASTROENTEROLOGY, 2004, 126 (04) : A722 - A723
  • [4] Peginterferon alfa-2a and ribavirin in African American and Caucasian patients with chronic hepatitis C, genotype 1
    Conjeevaram, HS
    Fried, MW
    Jeffers, LJ
    Terrault, N
    Wiley-Lucas, TE
    Afdhal, N
    Brown, RS
    Belle, SH
    Robuck, PR
    Howell, CD
    HEPATOLOGY, 2005, 42 (04) : 275A - 276A
  • [5] Balapiravir plus peginterferon alfa-2a (40KD)/ribavirin in a randomized trial of hepatitis C genotype 1 patients
    Nelson, David R.
    Zeuzem, Stefan
    Andreone, Pietro
    Ferenci, Peter
    Herring, Robert
    Jensen, Donald M.
    Marcellin, Patrick
    Pockros, Paul J.
    Rodriguez-Torres, Maribel
    Rossaro, Lorenzo
    Rustgi, Vinod K.
    Sepe, Thomas
    Sulkowski, Mark
    Thomason, Isaac R.
    Yoshida, Eric M.
    Chan, Anna
    Hill, George
    ANNALS OF HEPATOLOGY, 2012, 11 (01) : 15 - 31
  • [6] Peginterferon alfa-2a (40KD) (PEGASYS®) in combination with ribavirin in African American and Caucasian patients with chronic hepatitis CHCV genotype 1:: Safety and tolerability.
    Howell, C
    Jeffers, LS
    Cassidy, W
    Reddy, R
    Sheridan, S
    Ho, I
    Khouri, S
    Harb, G
    HEPATOLOGY, 2003, 38 (04) : 319A - 319A
  • [7] Peginterferon alfa-2a/ribavirin treatment in patients with chronic HCV genotype 1: Efficacy is improved in patients with early stages of fibrosis
    Shiffman, ML
    Fried, MW
    Marcellin, P
    Govindarajan, S
    Lopez-Talavera, JC
    Pockros, PJ
    GASTROENTEROLOGY, 2005, 128 (04) : A722 - A722
  • [8] Combination of Levovirin (LVV) and peginterferon alfa-2a (40 KD) (Pegasys®) fails to generate a virological response comparable to ribavirin (RBV, Copegus®) and peginterferon alfa-2a (40KD) in patients with chronic hepatitis
    Pockros, PJ
    Pessoa, MG
    Diago, M
    Martinelli, ADC
    Berg, T
    Germanidis, G
    Lai, MY
    Gomez, HR
    Goeser, T
    Roberts, S
    Sheen, IS
    Hsien, T
    Hinrichsen, HM
    Lee, SS
    Reindollar, R
    Sola, R
    Wilson, K
    Jorga, K
    Graham, P
    Jackson, H
    HEPATOLOGY, 2004, 40 (04) : 391A - 391A
  • [9] Early predictors of anemia in patients with hepatitis C genotype 1 treated with peginterferon alfa-2a (40KD) plus ribavirin
    Reau, Nancy
    Hadziyannis, Stephanos J.
    Messinger, Diethelm
    Fried, Michael W.
    Jensen, Donald M.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2008, 103 (08): : 1981 - 1988
  • [10] HIGH SUSTAINED VIROLOGIC RESPONSE RATES IN HCV GENOTYPE 1 RELAPSER PATIENTS RETREATED WITH PEGINTERFERON ALFA-2A (40KD) PLUS RIBAVIRIN FOR 72 WEEKS
    Kaiser, Stephan
    Lutze, Bettina
    Hass, Holer G.
    Werner, Christoph R.
    HEPATOLOGY, 2008, 48 (04) : 1140A - 1140A
12345